| Trial ID: | L0184 |
| Source ID: | NCT05254626
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis
|
| Acronym: |
--
|
| Status: |
Not yet recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Steatohepatitis
|
| Interventions: |
Drug: Dapagliflozin 10Mg Tab|Drug: Pioglitazone 30 mg
|
| Outcome Measures: |
NAFLD activity score (NAS)|NAFLD fibrosis score (NFS)|Fibro-controlled attenuated parameter (fibro CAP)|Serum Alanine Transaminase level (ALT)|Serum Aspartate Aminotransferase level (AST)|Serum Alkaline Phosphatase level (ALP)|Serum Gamma-glutamyl Transferase level (GGT)|Serum total and direct bilirubin.|Waist circumference|Body weight|Visceral and subcutaneous abdominal fat|Lipid profile|Glycated hemoglobin (HbA1C)|Fasting blood glucose level|Insulin resistance (HOMA-IR)|Quality of life Questionnaire (quality of life assessment)|Drugs adverse events
|
| Sponsor/Collaborators: |
Cairo University
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
160
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
March 2022
|
| Completion Date: |
August 2025
|
| Results First Posted: |
--
|
| Last Update Posted: |
February 24, 2022
|
| Locations: |
--
|
| URL: |
https://ClinicalTrials.gov/show/NCT05254626
|
